A smiling woman with shoulder-length wavy brown hair, wearing turquoise earrings and a dark gray top, against a softly blurred indoor background.

Rosalind Segal, M.D., Ph.D.

Professor of Neurobiology, Dana-Farber Cancer Institute
Dean for Graduate Education, Harvard Medical School

Rosalind Segal, MD, PhD – Faculty Profile

Professor of Neurobiology at the Dana-Farber Cancer Institute and Dean for Graduate Education at Harvard Medical School.

If you prefer, you can view the visual layout directly on Canva by Neuro Coordinator.

Contact

Email: roz_segal@hms.harvard.edu

Segal Lab website: segallab.dana-farber.org

The Aim

The Segal Lab studies neuronal signaling pathways in cancer and nerve cell responses to chemotherapy, aiming to develop better treatments for nervous system disorders and reduce a common side effect of chemotherapy: neuropathic pain.

The Impact

The Segal Lab is interested in extending our knowledge of neuronal signaling pathways to treat disorders of the nervous system. A particular area of interest is understanding how neurons contribute to cancers of the brain, and specifically how nerve cells respond to chemotherapies. This is especially important in cases where cancer treatments can cause damage to nerve cells, leading to neuropathic pain in patients.

The Segal Lab’s work aims to create more effective approaches to mitigate these side effects, as well as to better understand how signaling pathways in neurons can be leveraged to understand nervous system diseases.

A Closer Look

Dana-Farber Cancer Institute: Discovery Suggests Approach to Preventing Peripheral Neuropathy

This article describes research led by Rosalind Segal showing how a protein called Bcl-w helps protect nerve axons. The research suggests that restoring or mimicking Bcl-w may help prevent chemotherapy-induced peripheral neuropathy, which can cause numbness, tingling, and pain in the hands and feet.

Segal Lab research: Research at the Segal Lab

The Segal Lab researches how specific signaling pathways control brain tumor growth and neuron survival. This work aims to support the development of targeted therapies for brain cancers and treatments that prevent nerve degeneration.

Additional Profile Information

Rosalind Segal, MD, PhD, is a Professor of Neurobiology at the Dana-Farber Cancer Institute and Dean for Graduate Education at Harvard Medical School.

Publications View
An Architect of the Hindbrain: DDX3X Regulates Normal and Malignant Development.
Authors: Authors: Hwang GH, Segal RA.
Dev Cell
View full abstract on Pubmed
Roadmap for the Emerging Field of Cancer Neuroscience.
Authors: Authors: Monje M, Borniger JC, D'Silva NJ, Deneen B, Dirks PB, Fattahi F, Frenette PS, Garzia L, Gutmann DH, Hanahan D, Hervey-Jumper SL, Hondermarck H, Hurov JB, Kepecs A, Knox SM, Lloyd AC, Magnon C, Saloman JL, Segal RA, Sloan EK, Sun X, Taylor MD, Tracey KJ, Trotman LC, Tuveson DA, Wang TC, White RA, Winkler F.
Cell
View full abstract on Pubmed
Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems.
Authors: Authors: Staff NP, Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S.
Exp Neurol
View full abstract on Pubmed
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells.
Authors: Authors: Reitman ZJ, Paolella BR, Bergthold G, Pelton K, Becker S, Jones R, Sinai CE, Malkin H, Huang Y, Grimmet L, Herbert ZT, Sun Y, Weatherbee JL, Alberta JA, Daley JF, Rozenblatt-Rosen O, Condurat AL, Qian K, Khadka P, Segal RA, Haas-Kogan D, Filbin MG, Suva ML, Regev A, Stiles CD, Kieran MW, Goumnerova L, Ligon KL, Shalek AK, Bandopadhayay P, Beroukhim R.
Nat Commun
View full abstract on Pubmed
A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Authors: Authors: Pak E, MacKenzie EL, Zhao X, Pazyra-Murphy MF, Park PMC, Wu L, Shaw DL, Addleson EC, Cayer SS, Lopez BG, Agar NYR, Rubin LL, Qi J, Merk DJ, Segal RA.
Neuro Oncol
View full abstract on Pubmed
NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy.
Authors: Authors: Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman D, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, Mohile S, Paice J, Rowland JH, Salvemini D, Segal RA, Lavoie Smith E, McCaskill Stevens W, Janelsins MC.
J Natl Cancer Inst
View full abstract on Pubmed
Sonic Hedgehog Signaling is Blue: Insights from the Patched Mutant Mice.
Authors: Authors: Merk DJ, Segal RA.
Trends Neurosci
View full abstract on Pubmed
A transatlantic cooperation for enriched neuroscience training.
Authors: Authors: Witter MP, Karagogeos D, Van Bockstaele EJ, Segal RA.
Eur J Neurosci
View full abstract on Pubmed
A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO Inhibitors.
Authors: Authors: Zhao X, Pak E, Ornell KJ, Pazyra-Murphy MF, MacKenzie EL, Chadwick EJ, Ponomaryov T, Kelleher JF, Segal RA.
Cancer Discov
View full abstract on Pubmed
Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration.
Authors: Authors: Pease-Raissi SE, Pazyra-Murphy MF, Li Y, Wachter F, Fukuda Y, Fenstermacher SJ, Barclay LA, Bird GH, Walensky LD, Segal RA.
Neuron
View full abstract on Pubmed